– USA, MA – Torque Therapeutics, a clinical-stage, product-platform company developing proprietary, first-in-class Deep Primed adoptive cell transfer therapeutics with uniquely broad potential to treat patients with a wide range of hematologic and solid malignancies, announced the appointment of John Cox as CEO.
Douglas Cole, Lead Director of Torque and Managing Partner at Flagship Pioneering, said, “I am thrilled that John has taken on the role of CEO of Torque. His accomplishments delivering value to shareholders are among the most significant in the biotechnology industry. Over the course of his career, he has demonstrated his ability to advance and commercialize products, build teams, and guide and drive organizations. He is a true leader. I am excited to work with John as he leads the development of Torque’s growing pipeline of clinical and preclinical proprietary products, continues to build on Torque’s robust Deep Primed T Cell platform, and expands the Torque capital base.”
About John Cox
Mr. Cox was most recently Chief Executive Officer of Bioverativ. He led the Bioverativ spin-out from Biogen in 2016 and the sale of Bioverativ to Sanofi for $11.6B in 2018. He previously served in roles of increasing seniority at Biogen, ultimately as Executive Vice President of Pharmaceutical Operations and Technology overseeing global manufacturing facilities, supply chain operations, technical development, quality and engineering, and development and commercialization of Biogen’s biosimilars business.
“I am delighted to take leadership of Torque Therapeutics,” Mr. Cox said. “After the sale of Bioverativ, I assessed many opportunities to run a company that could really change patients’ lives. I believe Torque represents one of the most compelling approaches to do that.”
Cox went on, “Torque is poised to move the field of adoptive cell transfer from niche use in small groups of late-stage patients with particular hematologic malignancies to broad use across multiple groups of early- and late-stage patients with a broad range of hematologic and solid malignancies. Torque’s Deep Primed product-platform is the only approach that has been developed that combines the ability to address the inherent variability of each patient’s malignancy, safely harness the critical power of cytokines and other immune agonists, and cost-effectively manufacture therapeutic products. With a clinical trial of its first clinical candidate already underway, trials of its second and third clinical candidates slated to begin in the next two quarters, and additional product candidates advancing in the expanding pipeline, Torque has enormous potential to create value in the near term and beyond.”
Cox became Executive Chairman of Torque in January 2019. During his tenure as Executive Chairman, Torque successfully transitioned from a pre-clinical to a clinical-stage company, advanced multiple product candidates in its pipeline, expanded its team with key hires in business development and finance, received Fast Track designation for its lead TRQ-1501 product, and announced a collaboration with Thermo Fisher Scientific to manufacture Torque’s Deep Primed T Cell immunotherapies, as well as a clinical trial collaboration with Merck to evaluate its lead TRQ-1501 product in combination with Keytruda.
About Torque Therapeutics
Torque is a clinical-stage immuno-oncology company developing Deep-Primed T cell immunotherapy to direct immune power deep within the tumor microenvironment. Torque’s first product candidate—TRQ-1501 —is in Phase 1/2 clinical trial for solid tumors and hematologic cancers. The company is based in Cambridge, Massachusetts.
For more information: http://www.torquetx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
